Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.
Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L, Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano G. Criscitiello C, et al. Among authors: de placido s, de laurentiis m. Cancer Treat Rev. 2023 Nov;120:102618. doi: 10.1016/j.ctrv.2023.102618. Epub 2023 Aug 22. Cancer Treat Rev. 2023. PMID: 37639757 Review.
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, Marinelli A, De Laurentiis M, Varriale E, Petrella G, et al. De Placido S, et al. Among authors: de laurentiis m. Br J Cancer. 1995 Jun;71(6):1283-7. doi: 10.1038/bjc.1995.248. Br J Cancer. 1995. PMID: 7779724 Free PMC article. Clinical Trial.
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C. Bianco AR, et al. Among authors: de placido s, de laurentiis m. Ann N Y Acad Sci. 1993 Nov 30;698:330-8. doi: 10.1111/j.1749-6632.1993.tb17223.x. Ann N Y Acad Sci. 1993. PMID: 8279772 Clinical Trial. No abstract available.
Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues.
Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, Mullick WJ, Pettinato G, Schnitt SJ, Bianco AR, Ciardiello F. Panico L, et al. Among authors: de placido s, de laurentiis m. Int J Cancer. 1996 Jan 3;65(1):51-6. doi: 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0. Int J Cancer. 1996. PMID: 8543395
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G. Ciardiello F, et al. Among authors: de placido s, de laurentiis m. Int J Cancer. 2000 Mar 1;85(5):710-5. doi: 10.1002/(sici)1097-0215(20000301)85:5<710::aid-ijc18>3.0.co;2-4. Int J Cancer. 2000. PMID: 10699953
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas.
Pepe S, Ruggiero A, D'Acquisto M, De Laurentiis M, De Placido S, Sandomenico C, Staibano S, De Rosa G, Lucariello A, D'Armiento M, Bianco AR. Pepe S, et al. Among authors: de rosa g, de placido s, de laurentiis m. Cancer. 2000 Sep 1;89(5):1065-75. doi: 10.1002/1097-0142(20000901)89:5<1065::aid-cncr16>3.0.co;2-t. Cancer. 2000. PMID: 10964337
279 results